Cancer treatment and the risk of cancer death among Aboriginal and non-Aboriginal South Australians: analysis of a matched cohort study.
Aboriginal
Cancer
Cancer treatment
Disparity
Indigenous
Survival
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
29 Oct 2019
29 Oct 2019
Historique:
received:
16
12
2018
accepted:
13
09
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
24
1
2020
Statut:
epublish
Résumé
Aboriginal and Torres Strait Islander Australians have poorer cancer outcomes than other Australians. Comparatively little is known of the type and amount of cancer treatment provided to Aboriginal and Torres Strait Islander people and the consequences for cancer survival. This study quantifies the influence of surgical, systemic and radiotherapy treatment on risk of cancer death among matched cohorts of cancer cases and, the comparative exposure of cohorts to these treatments. Cancers registered among Aboriginal South Australians in 1990-2010 (N = 777) were matched with randomly selected non-Indigenous cases by sex, birth and diagnostic year, and primary site, then linked to administrative cancer treatment for the period from 2 months before to 13 months after diagnosis. Competing risk regression summarised associations of Indigenous status, geographic remoteness, comorbidities, cancer stage and treatment exposure with risk of cancer death. Fewer Aboriginal cases had localised disease at diagnosis (37.2% versus 50.2%) and they were less likely to: experience hospitalisation with cancer diagnosis, unadjusted odds ratio (UOR) = 0.76; 95%CI = 0.59-0.98; have surgery UOR = 0.65; 95%CI = 0.53-0.80; systemic therapies UOR = 0.64; 95%CI = 0.52-0.78; or radiotherapy, UOR = 0.76; 95%CI = 0.63-0.94. Localised disease carried lower risk of cancer death compared to advanced cases receiving surgery or systemic therapies, SHR = 0.34; 95%CI = 0.25-0.47 and SHR = 0.35; 95%CI = 0.25-0.48. Advanced disease and no treatment carried higher risk of cancer death, SHR = 1.82; 95%CI = 1.26-2.63. The effects of treatment did not differ between Aboriginal and non-Indigenous cohorts. However, comparatively less exposure to surgical and systemic treatments among Aboriginal cancer cases further complicated the disadvantages associated with geographic remoteness, advanced stage of disease and co-morbid conditions at diagnosis and add to disparities in cancer death. System level responses to improving access, utilisation and quality of effective treatments are needed to improve survival after cancer diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Aboriginal and Torres Strait Islander Australians have poorer cancer outcomes than other Australians. Comparatively little is known of the type and amount of cancer treatment provided to Aboriginal and Torres Strait Islander people and the consequences for cancer survival. This study quantifies the influence of surgical, systemic and radiotherapy treatment on risk of cancer death among matched cohorts of cancer cases and, the comparative exposure of cohorts to these treatments.
METHODS
METHODS
Cancers registered among Aboriginal South Australians in 1990-2010 (N = 777) were matched with randomly selected non-Indigenous cases by sex, birth and diagnostic year, and primary site, then linked to administrative cancer treatment for the period from 2 months before to 13 months after diagnosis. Competing risk regression summarised associations of Indigenous status, geographic remoteness, comorbidities, cancer stage and treatment exposure with risk of cancer death.
RESULTS
RESULTS
Fewer Aboriginal cases had localised disease at diagnosis (37.2% versus 50.2%) and they were less likely to: experience hospitalisation with cancer diagnosis, unadjusted odds ratio (UOR) = 0.76; 95%CI = 0.59-0.98; have surgery UOR = 0.65; 95%CI = 0.53-0.80; systemic therapies UOR = 0.64; 95%CI = 0.52-0.78; or radiotherapy, UOR = 0.76; 95%CI = 0.63-0.94. Localised disease carried lower risk of cancer death compared to advanced cases receiving surgery or systemic therapies, SHR = 0.34; 95%CI = 0.25-0.47 and SHR = 0.35; 95%CI = 0.25-0.48. Advanced disease and no treatment carried higher risk of cancer death, SHR = 1.82; 95%CI = 1.26-2.63.
CONCLUSION
CONCLUSIONS
The effects of treatment did not differ between Aboriginal and non-Indigenous cohorts. However, comparatively less exposure to surgical and systemic treatments among Aboriginal cancer cases further complicated the disadvantages associated with geographic remoteness, advanced stage of disease and co-morbid conditions at diagnosis and add to disparities in cancer death. System level responses to improving access, utilisation and quality of effective treatments are needed to improve survival after cancer diagnosis.
Identifiants
pubmed: 31665005
doi: 10.1186/s12913-019-4534-y
pii: 10.1186/s12913-019-4534-y
pmc: PMC6820943
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
771Subventions
Organisme : National Health and Medical Research Centre (AUS)
ID : GNT1072243
Références
Cancer Epidemiol. 2017 Jun;48:131-139
pubmed: 28511150
Int J Public Health. 2016 May;61(4):435-42
pubmed: 26427859
Gynecol Oncol. 2014 Jan;132(1):221-6
pubmed: 24016407
J Oncol Pract. 2013 Sep;9(5):e220-7
pubmed: 23943892
Aust Health Rev. 2004;27(2):68-79
pubmed: 15525239
Int J Clin Oncol. 2015 Aug;20(4):814-20
pubmed: 25557325
Lancet Oncol. 2008 Jun;9(6):585-95
pubmed: 18510990
Lancet. 2006 Jun 3;367(9525):1842-8
pubmed: 16753487
Cancer Causes Control. 2015 Dec;26(12):1813-24
pubmed: 26407955
Ann Surg Oncol. 2017 Feb;24(2):311-318
pubmed: 27766558
Cancer Epidemiol. 2016 Apr;41:132-8
pubmed: 26953842
Cancer Metastasis Rev. 2003 Mar;22(1):25-38
pubmed: 12716034
BMC Cancer. 2014 Jul 18;14:517
pubmed: 25037075
Cancer Epidemiol. 2018 Feb;52:75-82
pubmed: 29272753
IARC Sci Publ. 1980;(32):5-338
pubmed: 7216345
Aust Health Rev. 2019 Apr;43(2):217-223
pubmed: 29495978
Cancer Causes Control. 2003 Mar;14(2):109-21
pubmed: 12749716
Gynecol Oncol. 2016 Nov;143(2):334-345
pubmed: 26948694
BMC Cancer. 2017 Jun 2;17(1):398
pubmed: 28577351
BMJ Open. 2016 Dec 23;6(12):e012505
pubmed: 28011808
Gastroenterology. 2016 May;150(5):1135-1146
pubmed: 26836586
J Natl Cancer Inst. 2010 Oct 20;102(20):1584-98
pubmed: 20937991
Cancer Causes Control. 2017 Dec;28(12):1417-1427
pubmed: 29027594
Asia Pac J Clin Oncol. 2017 Oct;13(5):e224-e231
pubmed: 26997361
Intern Med J. 2006 Aug;36(8):498-505
pubmed: 16866654
Cancer Metastasis Rev. 2003 Mar;22(1):7-9
pubmed: 12716031
Aust J Rural Health. 2015 Feb;23(1):4-18
pubmed: 25689378
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1950-62
pubmed: 18708384
BMC Cancer. 2016 Apr 25;16:289
pubmed: 27112140
Cancer Causes Control. 2018 Mar;29(3):333-342
pubmed: 29429013
Eur J Cancer Care (Engl). 2016 Mar;25(2):208-13
pubmed: 26918683
Ann Am Thorac Soc. 2017 Mar;14(3):403-411
pubmed: 28118039
Popul Health Metr. 2017 Jul 3;15(1):24
pubmed: 28673318
Med Care. 2007 Jan;45(1):66-72
pubmed: 17279022
Ann Epidemiol. 2018 May;28(5):335-342
pubmed: 29503062
BMC Cancer. 2014 Mar 07;14:163
pubmed: 24606675
BMC Health Serv Res. 2019 Jun 14;19(1):387
pubmed: 31200700
J Epidemiol Community Health. 2010 Feb;64(2):117-23
pubmed: 20056966
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
Med J Aust. 2004 Aug 16;181(4):191-4
pubmed: 15310252
BMC Cancer. 2011 Oct 25;11:460
pubmed: 22026423
Ann Surg Oncol. 2017 Feb;24(2):299-301
pubmed: 27743226
Ann Oncol. 2006 Jan;17(1):5-19
pubmed: 16143594